BioSig to Present at Needham’s 24th Annual Virtual Growth Conference



BioSig is leaving 2021 after treating over 1,800 patient cases with the PURE EP â„¢ System.

Westport, CT, January 6, 2022 (GLOBE NEWSWIRE) – BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and experience the full range of ECG and intra-cardiac signals, today announced that it will present at the 24e Needham Growth Virtual Annual Conference Friday January 14e , 2022 at 4:15 p.m. ET.

To register for the live broadcast of the event, please click here.

A replay of the presentation will also be available on the website BioSig website.

For those interested in scheduling a one-to-one meeting with BioSig management, please contact your Needham representative.

The PURE EP â„¢ is an FDA-approved 510 (k) non-invasive Class II device designed to improve the efficiency and effectiveness of cardiac electrophysiology procedures. Clinical data acquired by the PURE EP â„¢ System in a multicenter study from the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic Jacksonville, and Massachusetts General Hospital were recently published in the Journal of Cardiovascular Electrophysiology and are available under electronic form with access via the Wiley Online Library. Study results showed a 93% consensus among blinded reviewers with an overall improvement of 75% in intracardiac signal quality and confidence in the interpretation of PURE EP â„¢ signals compared to conventional sources.

One in 18 Americans has an arrhythmia. Atrial fibrillation is the most common type of arrhythmia, affecting more than 33 million people worldwide, including more than 6 million in the United States. The number of people with atrial fibrillation is expected to reach 8 to 12 million by 2050.1. According to the Centers for Disease Control and Prevention (CDC), atrial fibrillation causes more than 750,000 hospitalizations in the United States each year, resulting in approximately $ 6 billion in health care spending per year.2.

About BioSig Technologies
BioSig Technologies is a medical technology company that markets a proprietary biomedical signal processing platform designed to improve signal fidelity and discover the full range of ECG and intracardiac signals. (www.biosig.com).

The Company’s first product, PURE EP ™ System is a computerized system for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology procedures (EP) in an EP laboratory. Nowadays, 73 doctors finished more 1,800 cases of patients with the PURE EP â„¢ system. The Company is in a targeted commercial launch of the PURE EP â„¢ system in the northeast, Texas, and Florida. The technology is regularly used in some of the top-ranked hospitals in the country, including St. David’s Medical Center in Austin, Texas, the Mayo Clinic campuses in Florida, Minnesota, and Arizona, and the University of Pennsylvania. in Philadelphia, Pennsylvania.

Forward-looking statements
This press release contains “forward-looking statements”. Such statements may be preceded by the words “intention”, “may”, “will”, “plans”, “expects”, “plans”, “projects”, “predicts”, “estimates”, “aims” , “Esteem”, “hopes”, “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the Company, and cannot be predicted or quantified and, by therefore, actual results may differ materially from those expressed or implied by these forward-looking statements. These risks and uncertainties include, without limitation, the risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future if necessary, (ii) our inability to manufacture our products and product candidates on a commercial scale by ourselves or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competitors; (v) the loss of one or more key executives or scientists; and (vi) difficulties in obtaining regulatory approval to market our products and product candidates. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements are set out in the documents filed by the company with the Securities and Exchange Commission (SEC), including the company’s annual report on the form 10-K and its Quarterly Report Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

1 Top 10 Things You Should Know About Heart Rate; Scripps Health.

2 Management of atrial fibrillation; Lisa Eramom MA, Medical Economics Journal, February 25, 2019, Volume 96, Number 4

CONTACT: Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133


Previous Nervous reaction on Wall Street to Fed minutes
Next City council holds first meeting in 2022